Drug
Carbon-14 clinical trials
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2008
Studies by the year they started
4 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2021 | 2 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 0
Bial R&D Investments, S.A. (1) · Haisco Pharmaceutical Group Co., Ltd. (1) · Sirtris, a GSK Company (1) · Angion Biomedica Corp (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Carbon-14 is read from its arms, and is right about nine times in ten.
Testing it · 4
- Mass Balance Recovery and Metabolite Identification of Carbon-14 BIA 28-6156CompletedPhase 1Bial R&D Investments, S.A.NCT05220072Written as Carbon-14 BIA 28-6156
- Study on Mass Balance of [14C]HSK39297 in Healthy Chinese Adult Male SubjectsCompletedPhase 1Haisco Pharmaceutical Group Co., Ltd.NCT06852092Written as Carbon-14 labeled HSK39297
- A Study to Assess the Absorption, Metabolism and Excretion of [14C]-ANG-3777Status unknownPhase 1Angion Biomedica CorpNCT04931524Written as carbon-14-[14C]-ANG-3777
- A Clinical Study to Evaluate the Pharmacokinetics and the Absolute Bioavailability of SRT2104 Given as a 250mg Oral Suspension and Intravenous Microdose of 100 µg Carbon-14 Radio-labeled SRT2104 in Healthy Male SubjectsCompletedPhase 1Sirtris, a GSK CompanyNCT00937872Written as Carbon-14 radio-labeled SRT2104
Codes
What other systems call Carbon-14 · ClinicalTrials.gg INT000632
- MeSH (NLM) C000615234Carbon-14One source NLM
- UNII (FDA) 7V68J5677OCARBON C-14Confirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000615234 | Carbon-14 | One source NLM |
| UNII (FDA) | 7V68J5677O | CARBON C-14 | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.